Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results

Simulations Plus, Inc. shared its financial results for the third quarter of fiscal 2026, concluding on May 31, 2026. The company, recognized for its contributions to model-informed and AI-driven drug development in the biopharma sector, reported a 7% growth in total revenue, reaching $21.9 million. Although software revenue remained stable at $12.6 million, accounting for 58% of the total revenue, other aspects saw noticeable improvements. It is noteworthy that these results are in comparison to the third quarter of 2025.